Any 0 3 0 3 O
other 4 9 4 9 O
life 10 14 10 14 O
- 14 15 14 15 O
threatening 15 26 15 26 O
, 26 27 26 27 O
non 28 31 28 31 O
- 31 32 31 32 O
cardiac 32 39 32 39 B-chronic_disease
disease 40 47 40 47 I-chronic_disease

Coronary 0 8 48 56 B-chronic_disease
event 9 14 57 62 I-chronic_disease
or 15 17 63 65 O
procedure 18 27 66 75 B-treatment
( 28 29 76 77 O
myocardial 29 39 77 87 B-chronic_disease
infarction 40 50 88 98 I-chronic_disease
, 50 51 98 99 O
unstable 52 60 100 108 B-chronic_disease
angina 61 67 109 115 I-chronic_disease
, 67 68 115 116 O
coronary 69 77 117 125 B-treatment
artery 78 84 126 132 I-treatment
bypass 85 91 133 139 I-treatment
, 91 92 139 140 O
surgery 93 100 141 148 B-treatment
or 101 103 149 151 O
coronary 104 112 152 160 B-treatment
angioplasty 113 124 161 172 I-treatment
) 124 125 172 173 O
in 126 128 174 176 O
the 129 132 177 180 O
previous 133 141 181 189 B-upper_bound
four 142 146 190 194 I-upper_bound
weeks 147 152 195 200 I-upper_bound
; 152 153 200 201 O
2)Hemoglobin 154 166 202 214 O
A1c 167 170 215 218 I-clinical_variable
> 171 172 219 220 O
10 172 174 220 222 B-lower_bound
% 174 175 222 223 I-lower_bound

HIV 0 3 224 227 B-chronic_disease
or 4 6 228 230 O
Hepatitis 7 16 231 240 B-chronic_disease
C 17 18 241 242 I-chronic_disease
positive 19 27 243 251 O
status 28 34 252 258 O

Hematocrit 0 10 259 269 B-clinical_variable
> 11 12 270 271 O
50 13 15 272 274 B-lower_bound
% 15 16 274 275 I-lower_bound

Hepatic 0 7 276 283 B-chronic_disease
disease 8 15 284 291 I-chronic_disease
( 16 17 292 293 O
transaminase 17 29 293 305 B-clinical_variable
> 30 31 306 307 O
3 32 33 308 309 B-lower_bound
times 34 39 310 315 O
normal 40 46 316 322 O
) 46 47 322 323 O
or 48 50 324 326 O
cirrhosis 51 60 327 336 B-chronic_disease

IPSS 0 4 337 341 B-clinical_variable
â‰¤ 5 6 342 343 O
19 7 9 344 346 B-upper_bound

Males 0 5 347 352 B-gender

PSA 0 3 353 356 B-clinical_variable
< 4 5 357 358 O
2.6 6 9 359 362 B-upper_bound
ng 10 12 363 365 I-upper_bound
/ 12 13 365 366 I-upper_bound
ml 13 15 366 368 I-upper_bound
or 16 18 369 371 O
< 19 20 372 373 O
3.75 21 25 374 378 B-upper_bound
ng 26 28 379 381 I-upper_bound
/ 28 29 381 382 I-upper_bound
ml 29 31 382 384 I-upper_bound
with 32 36 385 389 O
a 37 38 390 391 O
negative 39 47 392 400 O
prostate 48 56 401 409 B-treatment
biopsy 57 63 410 416 I-treatment
in 64 66 417 419 O
the 67 70 420 423 O
last 71 75 424 428 B-upper_bound
6 76 77 429 430 I-upper_bound
months 78 84 431 437 I-upper_bound

Participation 0 13 438 451 O
in 14 16 452 454 O
any 17 20 455 458 O
other 21 26 459 464 B-treatment
concurrent 27 37 465 475 I-treatment
clinical 38 46 476 484 I-treatment
trial 47 52 485 490 I-treatment

Renal 0 5 491 496 B-chronic_disease
impairment 6 16 497 507 I-chronic_disease
( 17 18 508 509 O
serum 18 23 509 514 B-clinical_variable
creatinine 24 34 515 525 I-clinical_variable
> 35 36 526 527 O
1.5 37 40 528 531 B-lower_bound
) 40 41 531 532 O

Subjects 0 8 533 541 O
on 9 11 542 544 O
insulin 12 19 545 552 B-treatment
, 19 20 552 553 O
metformin 21 30 554 563 B-treatment
or 31 33 564 566 O
sulfonylureas 34 47 567 580 B-treatment
can 48 51 581 584 O
participate 52 63 585 596 O
in 64 66 597 599 O
the 67 70 600 603 O
study 71 76 604 609 O
, 76 77 609 610 O
provided 78 86 611 619 O
that 87 91 620 624 O
minimal 92 99 625 632 O
changes 100 107 633 640 O
are 108 111 641 644 O
made 112 116 645 649 O
to 117 119 650 652 O
the 120 123 653 656 O
doses 124 129 657 662 O
during 130 136 663 669 O
the 137 140 670 673 O
study 141 146 674 679 O

Subjects 0 8 680 688 O
on 9 11 689 691 O
thiazolidinediones 12 30 692 710 B-treatment
, 30 31 710 711 O
statins 32 39 712 719 B-treatment
, 39 40 719 720 O
ACE 41 44 721 724 B-treatment
inhibitors 45 55 725 735 I-treatment
, 55 56 735 736 O
angiotensin 57 68 737 748 B-treatment
receptor 69 77 749 757 I-treatment
blockers 78 86 758 766 I-treatment
or 87 89 767 769 O
antioxidants 90 102 770 782 B-treatment
will 103 107 783 787 O
be 108 110 788 790 O
allowed 111 118 791 798 O
as 119 121 799 801 O
long 122 126 802 806 O
as 127 129 807 809 O
they 130 134 810 814 O
are 135 138 815 818 O
on 139 141 819 821 O
stable 142 148 822 828 O
doses 149 154 829 834 O
of 155 157 835 837 O
these 158 163 838 843 O
compounds 164 173 844 853 O
and 174 177 854 857 O
the 178 181 858 861 O
dosage 182 188 862 868 O
in 189 191 869 871 O
not 192 195 872 875 O
changed 196 203 876 883 O
during 204 210 884 890 O
the 211 214 891 894 O
study 215 220 895 900 O

The 0 3 901 904 O
lower 4 9 905 910 O
age 10 13 911 914 B-age
limit 14 19 915 920 O
was 20 23 921 924 O
decided 24 31 925 932 O
on 32 34 933 935 O
the 35 38 936 939 O
fact 39 43 940 944 O
that 44 48 945 949 O
in 49 51 950 952 O
our 52 55 953 956 O
study 56 61 957 962 O
on 62 64 963 965 O
hypogonadotrophic 65 82 966 983 B-chronic_disease
hypogonadism 83 95 984 996 I-chronic_disease
in 96 98 997 999 O
type 99 103 1000 1004 B-chronic_disease
2 104 105 1005 1006 I-chronic_disease
diabetic 106 114 1007 1015 I-chronic_disease
patients 115 123 1016 1024 O
, 123 124 1024 1025 O
the 125 128 1026 1029 O
youngest 129 137 1030 1038 O
subject 138 145 1039 1046 O
was 146 149 1047 1050 O
31 150 152 1051 1053 B-lower_bound
years 153 158 1054 1059 I-lower_bound
old 159 162 1060 1063 O

The 0 3 1064 1067 O
upper 4 9 1068 1073 O
age 10 13 1074 1077 B-age
limit 14 19 1078 1083 O
has 20 23 1084 1087 O
been 24 28 1088 1092 O
restricted 29 39 1093 1103 O
to 40 42 1104 1106 O
60 43 45 1107 1109 B-upper_bound
to 46 48 1110 1112 O
avoid 49 54 1113 1118 O
including 55 64 1119 1128 O
subjects 65 73 1129 1137 O
with 74 78 1138 1142 O
significant 79 90 1143 1154 O
age 91 94 1155 1158 O
- 94 95 1158 1159 O
related 95 102 1159 1166 O
declines 103 111 1167 1175 O
in 112 114 1176 1178 O
testosterone 115 127 1179 1191 B-clinical_variable
concentrations 128 142 1192 1206 I-clinical_variable

Use 0 3 1207 1210 O
of 4 6 1211 1213 O
an 7 9 1214 1216 O
investigational 10 25 1217 1232 B-treatment
agent 26 31 1233 1238 I-treatment
or 32 34 1239 1241 O
therapeutic 35 46 1242 1253 B-treatment
regimen 47 54 1254 1261 I-treatment
within 55 61 1262 1268 O
30 62 64 1269 1271 B-upper_bound
days 65 69 1272 1276 I-upper_bound
of 70 72 1277 1279 O
study 73 78 1280 1285 O

Use 0 3 1286 1289 O
of 4 6 1290 1292 O
over 7 11 1293 1297 B-treatment
the 12 15 1298 1301 I-treatment
counter 16 23 1302 1309 I-treatment
health 24 30 1310 1316 I-treatment
supplements 31 42 1317 1328 I-treatment
which 43 48 1329 1334 I-treatment
contain 49 56 1335 1342 I-treatment
androgens 57 66 1343 1352 I-treatment

Use 0 3 1353 1356 O
of 4 6 1357 1359 O
testosterone 7 19 1360 1372 B-treatment
in 20 22 1373 1375 O
the 23 26 1376 1379 O
past 27 31 1380 1384 O

age 0 3 1385 1388 B-age
30 4 6 1389 1391 B-lower_bound
- 6 7 1391 1392 O
60 7 9 1392 1394 B-upper_bound
years 10 15 1395 1400 I-upper_bound

h 0 1 1401 1402 O
/ 1 2 1402 1403 O
o 2 3 1403 1404 O
prostate 4 12 1405 1413 B-cancer
carcinoma 13 22 1414 1423 I-cancer

